Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference? Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Second line chemotherapy with cisplatin (C) plus paclitaxel (P) for chemo refractory and resistant SCLC patients (pts). Did it change the overall disease’s prognosis? Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003
Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma? Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
Difference of patient background with pneumonia between monotherapy and combination Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Using remote directly observed therapy (R-DOT) for optimising asthma therapy. Source: International Congress 2017 – Small airways, long distances and large databases in paediatric asthma Year: 2017
Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021
Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box Source: ERJ Open Res, 5 (1) 00185-2018; 10.1183/23120541.00185-2018 Year: 2019
Clinical predictors for long-term benefit of cetuximab maintenance therapy – Single center subanalysis of the GEMTAX IV trial Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Which method is effective in patient with asthma to guide the treatment? (2 year follow-up study) Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE) Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005
Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015
Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017
Gemcitabine (G) or vinorelbine (V)? What's the best drug in combination with a platinium-derivative for the treatment of locally advanced and metastatic non small cell lung cancer (NSCLC)? A 6 years retrospective study Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003